Hutchison China Meditech Limited Director's Share Dealing (0283O)

TIDMHCM

RNS Number : 0283O

Hutchison China Meditech Limited

01 November 2016

Director's Share Dealing

London: Tuesday, November 1, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an average price of GBP18.453305 per share between October 24, 2016 and October 28, 2016 under a personal share trading plan (the "Plan"). Pursuant to the Plan, a total of 20,000 Ordinary Shares will be sold between October 24, 2016 and November 23, 2016 (inclusive). The Plan (and the previous sale of 15,000 Ordinary Shares made by Mr Howell on October 7, 2016) has been put in place to facilitate financial settlement arising from a marital separation agreement.

Following the above sale of 10,000 Ordinary Shares, the holding of Mr Howell is 128,600 Ordinary Shares, representing approximately 0.21% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 
 1     Details of the person discharging managerial responsibilities/person closely associated 
----  -------------------------------------------------------------------------------------------------------------- 
  a)    Name                                                           Mr Michael Howell 
----  -------------------------------------------------------------  ----------------------------------------------- 
 2     Reason for the notification 
----  -------------------------------------------------------------------------------------------------------------- 
  a)    Position/status                                                Independent Non-executive Director of Chi-Med 
----  -------------------------------------------------------------  ----------------------------------------------- 
  b)    Initial notification/Amendment                                 Initial notification 
----  -------------------------------------------------------------  ----------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
        or auction monitor 
----  -------------------------------------------------------------------------------------------------------------- 
  a)    Name                                                           Hutchison China MediTech Limited 
----  -------------------------------------------------------------  ----------------------------------------------- 
  b)    LEI                                                            N/A 
----  -------------------------------------------------------------  ----------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and (iv) each place where transactions have been 
        conducted 
----  -------------------------------------------------------------------------------------------------------------- 
  a)    Description of the financial instrument, type of instrument    Ordinary Shares of US$1.00 each 
         Identification code                                            DI ISIN: KYG4672N1016 
                                                                        ADS ISIN: US44842L1035 
----  -------------------------------------------------------------  ----------------------------------------------- 
 
 
  b)    Nature of the transaction    Sale of 10,000 Ordinary Shares between October 24, 2016 and October 28, 2016 at 
                                     an average 
                                     price of GBP18.453305 
----  ---------------------------  ----------------------------------------------------------------------------------- 
  c)    Price(s) and volume(s)        Price(s)    Volume(s) 
                                      ----------  ---------- 
                                       GBP18.25       339 
                                      ----------  ---------- 
                                       GBP18.30      2,661 
                                      ----------  ---------- 
                                       GBP18.40      1,000 
                                      ----------  ---------- 
                                       GBP18.50      3,500 
                                      ----------  ---------- 
                                       GBP18.60      2,500 
                                      ----------  ---------- 
----  ---------------------------  ----------------------------------------------------------------------------------- 
  d)    Aggregated information       Aggregated volume: 10,000 
         -  Aggregated volume         Price information: GBP18.453305 
         -  Price 
----  ---------------------------  ----------------------------------------------------------------------------------- 
  e)    Date of the transaction      2016-10-24; 14:07 - disposal of 339 Ordinary Shares 
                                      2016-10-25; 14:05 - disposal of 661 Ordinary Shares 
                                      2016-10-25; 14:44 - disposal of 2,000 Ordinary Shares 
                                      2016-10-25; 15:29 - disposal of 1,000 Ordinary Shares 
                                      2016-10-26; 13:57 - disposal of 3,000 Ordinary Shares 
                                      2016-10-28; 12:48 - disposal of 2,500 Ordinary Shares 
                                      2016-10-28; 14:09 - disposal of 500 Ordinary Shares 
----  ---------------------------  ----------------------------------------------------------------------------------- 
  f)    Place of the transaction     London Stock Exchange (XLON) 
----  ---------------------------  ----------------------------------------------------------------------------------- 
 

NOTES TO EDITORS

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

 
Investor Enquiries 
Christian Hogg, CEO               [phone] 
 
International Media Enquiries 
Anthony Carlisle,                 [phone] (Mobile)   [e-mail] 
 Citigate Dewe Rogerson 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications    [phone] (Mobile)  [e-mail] 
 
Susan Duffy, BMC Communications   [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group        [phone] (Mobile)  [e-mail] 
 
David Dible,                      [phone] (Mobile)   [e-mail] 
 Citigate Dewe Rogerson 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts       [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFESLSLLIIR

(END) Dow Jones Newswires

November 01, 2016 10:57 ET (14:57 GMT)